Acute Respiratory Distress Syndrome, Critical Illness
Conditions
Keywords
Acute Respiratory Distress Syndrome, Critical Illness, Randomized Controlled Trial, Ulinastatin
Brief summary
Since strategies were applied in intensive care medicine, including low tidal volume ventilation, fluid resuscitation, use of antibiotics, restrictive transfusion strategy and bundle of ventilator therapy, the incidence of Acute Respiratory Distress Syndrome (ARDS) has been decreased recent years. However, the mortality of severe ARDS is still higher to 45%. Few medications did were indicated to be effective in working on development of ARDS. Different with other disease, ARDS were difficult to prevent in its later stage like a domino effect. The medication interventions are all used after ARDS was developed, including ulinastatin. The investigators hypothesized that the key point in failure of medication therapy is the delay timing of medication intervention. If given the preventive strategy, such as ulinastatin, the incidence or the severity of ARDS might be decreased. Therefore this is a randomized controlled trial to test the hypothesis of the preventive effect of ulinastatin in ARDS. This is a multi-center, randomized, double blinded, placebo controlled study.
Detailed description
Since strategies were applied in intensive care medicine, including low tidal volume ventilation, fluid resuscitation, use of antibiotics, restrictive transfusion strategy and bundle of ventilator therapy, the incidence of Acute Respiratory Distress Syndrome (ARDS) has been decreased recent years. However, the mortality of severe ARDS is still higher to 45%. Few medications did were indicated to be effective in working on development of ARDS. Different with other disease, ARDS were difficult to prevent in its later stage like a domino effect. The medication interventions are all used after ARDS was developed, including ulinastatin. The investigators hypothesized that the key point in failure of medication therapy is the delay timing of medication intervention. If given the preventive strategy, such as ulinastatin, the incidence or the severity of ARDS might be decreased. Ulinastatin is a urinary trypsin inhibitor (UTI) that inhibits various inflammatory proteases has been widely used in China, Japan, and Korea for the treatment of patients with inflammatory disorders, postoperative organs protection, shock, and pancreatitis. Therefore this is a randomized controlled trial to test the hypothesis of the preventive effect of ulinastatin in ARDS. This is a multi-center, randomized, double blinded, placebo controlled study.
Interventions
DRUGUlinastatin
200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
OTHERUsual care
Usual care in ICU.
Sponsors
Chinese PLA General Hospital
The First Affiliated Hospital of Zhengzhou University
Peking University Shenzhen Hospital
Central Hospital of Zi Bo
Beijing Anzhen Hospital
The Second Affiliated Hospital of Dalian Medical University
First Affiliated Hospital of Guangxi Medical University
Beijing Shijitan Hospital Affiliated to Capital Medical University
Peking University Third Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients should be more than 18 years old * Patients are expected to living within 72 hours of ICU admission * Patients' Lung Injury Prediction Score (LIPS) more than 4 and got at least 1 risk factors as below: bacteremia, sepsis or sepsis shock, pneumonia, multiple fractures, pulmonary contusion, aspiration, multiple blood transfusion, severe acute pancreatitis.
Exclusion criteria
Patients will be excluded when they are * diagnosed as ARDS * without written informed consent * with HIV infection * with other immunologic deficiency (leukaemia, immune deficiency syndrome, etc) * with organ transplantation or bone marrow transplantation * with chronic pulmonary disease (except for Chronic Obstructive Pulmonary Disease (COPD) or asthma) * with angitis * with neutropenia (except for secondary to sepsis) * using granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor * using asprin or clopidogrel * using glucocorticoid * withdrawing treatment * treated by Xuebijing, thymosin, or intravenous immunoglobulin 1 month before enrollment * enrolled in other clinical trials 3 months before enrollment * being pregnancy * being lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of ARDS | 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality of 28 days | 0-28 days | — |
| Mortality of 60 days | 0-60 days | — |
| Total cost in admission | 3 years | — |
| Adverse events related to drugs. | 3 years | — |
| The incidence of other organ disorders | 3 years | — |
| The number of patients who need mechanical ventilation | 3 years | — |
| Lengths of mechanical ventilation | 3 years | — |
| Lengths of ICU | 3 years | — |
| Lengths of stay | 3 years | — |
| The numbers of ARDS patients who meet the criteria for mild, moderate, and severe using the Berlin Definition, separately. | 3 years | The severity of ARDS will be assessed by the Berlin Definition in mild, moderate and severe ARDs according to oxygenation. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 3 years | Including white blood cell decrease, eosinophils increase, nausea, vomiting, diarrhoea, liver enzymes increase, allergy, adverse events in injection sites and etc. |
Countries
China
Outcome results
None listed